Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities
Name
vaccines-09-01490-v2.pdf
Size
6.23 MB
Format
Unknown
Checksum (MD5)
bb256bd2e3eb495ff559ec7fc121a5b9
Author(s)
Ghattas, Majed
Dwivedi, Garima
Lavertu, Marc
Alameh, Mohamad-Gabriel
Date Issued
December 2021
Publisher
Multidisciplinary Digital Publishing Institute
Citation
Vaccines 9 (12): 1490 (2021)
Version
Final published version
Abstract
Vaccination is a key component of public health policy with demonstrated cost-effective benefits in protecting both human and animal populations. Vaccines can be manufactured under multiple forms including, inactivated (killed), toxoid, live attenuated, Virus-like Particles, synthetic peptide, polysaccharide, polysaccharide conjugate (glycoconjugate), viral vectored (vector-based), nucleic acids (DNA and mRNA) and bacterial vector/synthetic antigen presenting cells. Several processes are used in the manufacturing of vaccines and recent developments in medical/biomedical engineering, biology, immunology, and vaccinology have led to the emergence of innovative nucleic acid vaccines, a novel category added to conventional and subunit vaccines. In this review, we have summarized recent advances in vaccine technologies and platforms focusing on their mechanisms of action, advantages, and possible drawbacks.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3390/vaccines9121490
